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Abstract
Background: A substantial proportion of multiple sclerosis (MS) patients discontinue interferon-
beta (IFNβ) treatment due to various adverse effects, most of which emerge at the early phase after
initiation of the treatment and then diminish with time. At present, the molecular mechanism
underlying IFNβ-related adverse effects remains largely unknown. The aim of this study is to
identify a comprehensive list of early IFNβ-responsive genes (IRGs) in peripheral blood
mononuclear cells (PBMC) that may play a key role in induction of adverse effects.
Methods: Total RNA of PBMC exposed to 50 ng/ml recombinant human IFNβ for 3 to 24 hours
in vitro was processed for cDNA microarray analysis, followed by quantitative real-time RT-PCR
analysis.
Results: Among 1,258 genes on the array, IFNβ elevated the expression of 107 and 87 genes, while
it reduced the expression of 22 and 23 genes at 3 and 24 hours, respectively. Upregulated IRGs
were categorized into conventional IFN-response markers, components of IFN-signaling pathways,
chemokines, cytokines, growth factors, and their receptors, regulators of apoptosis, DNA damage,
and cell cycle, heat shock proteins, and costimulatory and adhesion molecules. IFNβ markedly
upregulated CXCR3 ligand chemokines (SCYB11, SCYB10 and SCYB9) chiefly active on effector T
helper type 1 (Th1) T cells, and CCR2 ligand chemokines (SCYA8 and SCYA2) effective on
monocytes, whereas it downregulated CXCR2 ligand chemokines (SCYB2, SCYB1 and IL8)
primarily active on neutrophils.
Conclusion:  IFNβ immediately induces a burst of gene expression of proinflammatory
chemokines in vitro that have potential relevance to IFNβ-related early adverse effects in MS
patients in vivo.
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Background
Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS) white matter
mediated by an autoimmune process, whose develop-
ment is triggered by a complex interplay of both genetic
and environmental factors [1]. Administration of inter-
feron-gamma (IFNγ) induced acute relapses, along with
activation of the systemic immune response [2], suggest-
ing that T-lymphocytes producing proinflammatory T
helper type 1 (Th1) cytokines play a pivotal role in the
immunopathogenesis of MS. In contrast, interferon-beta
(IFNβ) significantly reduces the frequency of clinical exac-
erbations and delays the progression of disability in
relapsing-remitting MS (RRMS), accompanied by a reduc-
tion in the number of new brain lesions on MRI [3,4]. Fur-
thermore, an early initiation of IFNβ delays the
conversion to clinically definite MS in the patients who
experienced a first demyelinating event [5]. Although the
precise mechanism underlying therapeutic effects of IFNβ
on MS remains to be fully elucidated, previous studies
proposed several possibilities, including the inhibition of
Th1 cell development [6], induction of Th2 immune devi-
ation [7], restoration of function of the disrupted blood-
brain barrier [8], and downregulation of IFNγ-induced
expression of class II major histocompatibility complex
(MHC) molecules [9].
Although clinical benefits of IFNβ in MS are meaningful,
approximately one-third of the patients receiving IFNβ
therapy suffered from a higher or identical annual relapse
rate on treatment [10]. New lesion formation on MRI dur-
ing the treatment correlates with poor response to IFNβ
[11]. Furthermore, a substantial proportion of the
patients discontinued IFNβ treatment because of various
adverse effects, including skin reactions, flu-like symp-
toms, leukocytopenia, liver dysfunction, depression and
amenorrhea [12]. The molecular mechanisms accounting
for IFNβ-related adverse effects remain unknown,
although most of these emerge at the early phase after ini-
tiation of the treatment, and then diminish with time
[12]. At present, no biologically relevant markers capable
of predicting either therapeutic or detrimental responses
of IFNβ in MS are available [13].
DNA microarray technology is a novel approach that
allows us to systematically monitor the expression of a
large number of genes. It has given new insights into the
complexity of molecular interactions promoting the
autoimmune process in MS [14]. IFNβ induces a complex
pattern of gene regulation in peripheral blood mononu-
clear cells (PBMC) of MS [15]. Recently, we studied the
gene expression profile of CD3+ T cells isolated from
PBMC of 13 Japanese MS patients before and after treat-
ment with IFNβ-1b by analyzing a custom cDNA microar-
ray containing a set of well-annotated, immunologically
relevant genes. IFNβ upregulates the expression of 7 IFNβ-
responsive genes (IRGs) during the treatment [16]. A fol-
lowing study performed on RRMS patients receiving
IFNβ-1a supported our observations [17]. More recently,
we found that the vast majority of genes expressed in
CD3+  T cells differentially between 72 untreated MS
patients and 22 healthy controls are categorized into
apoptosis regulators [18]. Regarding the gene expression
profile of IFNβ responders in MS, baseline levels of IL-
12p35 mRNA are significantly lower in the responders
[19]. Downregulation of IL-8 expression in PBMC during
IFNβ treatment distinguishes the responders from nonre-
sponders in RRMS [20]. IFNβ responders differ from non-
responders in the kinetics of expression of IRGs at 3 and 6
months after starting the treatment [21]. A three-dimen-
sional model of gene triplets detected by RT-PCR analysis
predicts IFNβ response status in RRMS [22]. However, all
of previous observations do not clearly illustrate the
molecular basis of complex biological effects of IFNβ in
MS. Furthermore, no databases of immediate early IRGs
in PBMC are currently available.
The present study is designed to identify a comprehensive
list of immediate early IRGs in PBMC with potential rele-
vance to IFNβ-related early adverse effects in MS.
Methods
Treatment of peripheral blood lymphocytes with IFNβ
PBMC were isolated from heparinized blood by centrifu-
gation on a Ficoll density gradient. PBMC were suspended
at 5 × 106 cells/ml in RPMI 1640 medium containing 10%
fetal bovine serum, 2 mM L-glutamine, 55 µM 2-mercap-
toethanol, 100 U/ml penicillin, and 100 µg/ml strepto-
mycin (culture medium). The cells were incubated in a
5%CO2/95% air incubator at 37°C for 3 hours to charac-
terize the immediate response or for 24 hours to detect the
early response, in the culture medium with or without
inclusion of 50 ng/ml recombinant human IFNβ (a spe-
cific activity of = 2 × 107 units/mg, PeproTech, London,
UK), 50 ng/ml recombinant human IFNγ (a specific activ-
ity of = 2 × 107 units/mg, PeproTech), 50 ng/ml recom-
binant human TNFα (a specific activity of = 2 × 107 units/
mg, PeproTech), or 50 ng/ml recombinant human IL-1β
(a specific activity of = 1 × 107 units/mg, PeproTech). They
were then processed for RNA preparation as described pre-
viously [16,18,21]. Written informed consents were
obtained from the subjects involved in the present study
according to the form approved by the Ethics Committee
of National Center of Neurology and Psychiatry (NCNP),
Tokyo, Japan. The samples of the subjects #1, #2 and #4
were processed for both microarray and real-time RT-PCR
analysis, while those of the subject #3 were studied only
by real-time RT-PCR analysis.BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Quantitative real-time RT-PCR analysis
DNase-treated total RNA was processed for cDNA synthe-
sis using oligo(dT)12–18 primers and SuperScript II reverse
transcriptase (Invitrogen, Carlsbad, CA). cDNA was
amplified by PCR in LightCycler ST300 (Roche Diagnos-
tics, Tokyo, Japan) using SYBR Green I dye and the primer
sets listed in Table 1. To calibrate the concentration of
mRNA levels in test cDNA samples, serially-diluted puri-
fied PCR products generated by conventional RT-PCR (a
10-fold dilution from 1 pg/ml to 0.0001 pg/ml) were
amplified in parallel. The levels of expression of target
genes were standardized against those of the glyceralde-
hyde-3-phosphate dehydrogenase (G3PDH) gene
detected in the identical cDNA samples. The assays were
performed in triplicate measurements of the same sample
and the results were expressed as the average with stand-
ard error.
cDNA microarray analysis
The present study utilized a custom microarray containing
duplicate spots of 1,258 cDNA immobilized on a poly-L-
lysine-coated slide glass (Hitachi Life Science, Kawagoe,
Saitama, Japan) [16,18,21]. They were prepared by PCR of
well-annotated genes, selected from cytokines, growth fac-
tors and their receptors, apoptosis regulators, oncogenes,
transcription factors, cell cycle regulators and housekeep-
ing genes. The complete gene list is shown in Additional
file 1. Five µg of purified RNA was in vitro amplified and
antisense RNA (aRNA) was processed for microarray anal-
ysis. aRNA derived from IFNβ-treated PBMC was labeled
with a fluorescent dye Cy5, while aRNA of untreated
PBMC was labeled with Cy3 by reverse transcriptase reac-
tion. The arrays were hybridized at 62°C for 17 hours in
the hybridization buffer containing equal amounts of
Cy3- or Cy5-labeled cDNA, and they were then scanned at
two different photomultiplier tube (PMT) gains by the
ScanArray 5000 scanner (GSI Lumonics, Boston, MA).
The data were analyzed by using the QuantArray software
(GSI Lumonics). The fluorescence intensities (FI) of indi-
vidual spots were quantified following global normaliza-
tion between Cy3 and Cy5 signals. The average of FI of
duplicate spots was calculated, then the ratio of FI of Cy5
signal versus FI of Cy3 signal exceeding 2.0 was defined as
significant upregulation, whereas the ratio smaller than
0.5 was considered as substantial downregulation. The
impact of inter-experiment variability was validated by
analyzing a scatter plot (see Additional file 2).
The IFN-regulated expression of the genes we identified
was verified by computerized search of PubMed database
and IFN Stimulated Gene (ISG) database [23].
Results
Microarray analysis identified immediate early IFNβ-
responsive genes in PBMC
Among 1,258 genes on the array, IFNβ treatment for 3
hours elevated the expression of 107 genes in PBMC iso-
lated from a 46 year-old healthy man (the subject #1),
while it reduced the expression of 22 genes (see Addi-
tional files 3 and 4 for the complete list). IFNβ treatment
for 24 hours upregulated 87 genes and downregulated 23
genes (see Additional files 5 and 6 for the complete list).
Sixty-nine genes were upregulated at both 3 and 24 hours,
while only two genes such as FOS and IL1A were down-
regulated at both. The IRGs upregulated at both time
points contained 11 in vivo IRGs reported previously by us
[16], including IFIT1 (IFI56), ISG15 (G1P2), IFIT4
(IFI60), IFI27, G1P3 (IFI6-16), IRF7, ABCB2 (TAP1),
ATF3, IFITM1 (IFI17), SULT1C1, and TNFAIP6, whose
expression was elevated in T cells and non-T cells ex vivo,
isolated from 13 RRMS patients during IFNβ treatment for
3 to 6 months. Top 20 most significant genes, either
Table 1: Primers utilized for real-time RT-PCR analysis























NM_002089 5'cccgcatcgcccatggttaagaaa3' 5'tcttctgttcctgtaaggcagggc3' 131
FOS NM_005252 5'gagctggtgcattacagagaggag3' 5'ggacttgagtccacacatggatgc3' 140
RGS14 NM_006480 5'tgacagctacccaacagtccagga3' 5'agggattgggggtgagcttgttga3' 222
G3PDH NM_002046 5'ccatgttcgtcatgggtgtgaacca3' 5'gccagtagaggcagggatgatgttc3' 251
Abbreviations: ISG15, interferon-stimulated gene 15; SCYB10, small inducible cytokine subfamily B, member 10; SCYA8, small inducible cytokine 
subfamily A, member 8; SCYA2, small inducible cytokine subfamily A, member 2; SCYB2, small inducible cytokine subfamily B, member 2; FOS, 
cellular oncogene c-fos; RGS14, regulator of G-protein signaling 14; and G3PDH, glyceraldehyde-3-phosphate dehydrogenaseBMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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upregulated or downregulated, are listed in Table 2 and
Table 3, respectively. All of top 20 upregulated genes were
found as known IRGs identified in various cell types by
searching through PubMed and ISG databases.
The upregulated IRGs in the complete lists (see Additional
files 3 and 5) were classified into several functional cate-
gories following; (i) conventional IFN-response markers
(n = 12), (ii) components of classical and Toll-like recep-
tor (TLR)-dependent IFN-signaling pathways (n = 12),
(iii) chemokines and their receptors (n = 11), (iv)
cytokines, growth factors and their receptors (n = 17), (v)
apoptosis, DNA damage, and cell cycle regulators (n =
29), (vi) heat shock proteins (n = 9), and (vii) costimula-
tory and adhesion molecules (n = 7) (Table 4). The chem-
okine and chemokine receptor group included both CXC
and CC chemokines and their receptors, such as SCYB11
(CXCL11, I-TAC), SCYB10 (CXCL10, IP-10), SCYA8
(CCL8, MCP2), SCYB9 (CXCL9, MIG), SCYA2 (CCL2,
MCP1), CCR5, SCYA4 (CCL4, MIP1B), IL8RB (CXCR2),
Table 2: Top 20 upregulated genes in PBMC following exposue to IFNβ
No. Cy5/Cy3 ratio Symbol GenBank Gene name
at 3 hours
11 8 8 . 5 0 I F I T 1 X03557 interferon-induced protein with tetratricopeptide repeats 1 (IFI56)
2 149.82 SCYB11 AF030514 chemokine (C-X-C motif) ligand 11 (CXCL11, IP-9, I-TAC)
3 81.81 ISG15 M13755 interferon-stimulated gene ISG15 (G1P2)
4 67.84 IFIT4 AF083470 interferon-induced protein with tetratricopeptide repeats 4 (IFI60)
5 66.38 MX1 M30817 myxovirus resistance protein 1 (MXA)
6 64.43 SCYB10 X02530 chemokine (C-X-C motif) ligand 10 (CXCL10, IP-10)
7 55.01 SCYA8 Y10802 chemokine (C-C motif) ligand 8 (CCL8, MCP2)
8 36.88 SCYB9 X72755 chemokine (C-X-C motif) ligand 9 (CXCL9, MIG)
9 35.14 TNFSF10 U37518 tumor necrosis factor superfamily, member 10 (TRAIL)
10 32.86 MX2 M30818 myxovirus resistance protein 2 (MXB)
11 21.99 IFI27 X67325 interferon alpha-inducible protein 27
12 21.98 G1P3 X02492 interferon alpha-inducible protein (IFI6-16), isoform a
13 19.26 ISG20 U88964 interferon-stimulated gene ISG20
14 19.12 STAT1 M97935 signal transducer and activator of transcription 1, isoform alpha
15 13.71 IRF7 U53830 interferon-regulatory factor 7, isoform alpha
16 13.44 CCNA1 U66838 cyclin A1
17 12.72 IL6 M14584 interleukin 6
18 10.86 IL1RN X53296 interleukin 1 receptor antagonist, isoform 1
19 10.47 SCYA2 S71513 chemokine (C-C motif) ligand 2 (CCL2, MCP1)
20 9.91 STAT2 M97934 signal transducer and activator of transcription 2
at 24 hours
1 193.19 SCYA8 Y10802 chemokine (C-C motif) ligand 8 (CCL8, MCP2)
21 2 4 . 7 7 I F I T 1 X03557 interferon-induced protein with tetratricopeptide repeats 1 (IFI56)
3 107.21 IFI27 X67325 interferon alpha-inducible protein 27
4 70.51 ISG15 M13755 interferon-stimulated gene ISG15 (G1P2)
5 53.22 SCYB11 AF030514 chemokine (C-X-C motif) ligand 11 (CXCL11, IP-9, I-TAC)
6 38.07 MX1 M30817 myxovirus resistance protein 1 (MXA)
7 37.95 IFIT4 AF083470 interferon-induced protein with tetratricopeptide repeats 4 (IFI60)
8 31.56 SCYB10 X02530 chemokine (C-X-C motif) ligand 10 (CXCL10, IP-10)
9 23.65 G1P3 X02492 interferon alpha-inducible protein (IFI6-16), isoform a
10 23.10 TNFSF10 U37518 tumor necrosis factor superfamily, member 10 (TRAIL)
11 21.31 MX2 M30818 myxovirus resistance protein 2 (MXB)
12 20.68 PDGFRL D37965 platelet-derived growth factor receptor-like protein
13 15.95 CD80 M27533 CD80 antigen (B7-1)
14 13.99 IRF7 U53830 interferon-regulatory factor 7, isoform alpha
15 13.93 IL1RN X53296 interleukin 1 receptor antagonist, isoform 1
16 13.31 ISG20 U88964 interferon-stimulated gene ISG20
17 11.81 IFITM1 J04164 interferon induced transmembrane protein 1 (IFI17)
18 8.67 SCYA2 S71513 chemokine (C-C motif) ligand 2 (CCL2, MCP1)
19 8.54 IL6 M14584 interleukin 6
20 8.51 IL8RB L19593 interleukin 8 receptor beta (CXCR2)
Top 20 upregulated genes in PBMC of the subject #1 (a 46 year-old healthy man) by exposure to 50 ng/ml recombinant human IFNβ for 3 or 24 
hours are listed with Cy5/Cy3 signal intensity ratio, gene symbol, GenBank accession number, and gene name. In vivo IRGs in T cells and non-T cells 
of RRMS patients reported previously (Ref. 16) are underlined.BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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SCYA3 (CCL3, MIP1A), SCYA19 (CCL19, MIP3B) and
SCYA13 (CCL13, MCP4). It is worthy to note that both
CXCR3 ligand chemokines (SCYB11, SCYB10 and
SCYB9) and CCR2 ligand chemokines (SCYA10 and
SCYA2) were clustered in top 20 genes greatly elevated at
3 and 24 hours of IFNβ treatment (Table 2). With respect
to top 20 downregulated genes, four genes such as SCYB2
(CXCL2, GRO2), SCYB1 (CXCL1, GRO1), IL8 (SCYB8,
CXCL8), and SCYA24 (eotaxin-2) were categorized into
the chemokine group (Table 3). Among them, SCYB2,
SCYB1 and IL8, whose expression was reduced immedi-
ately at 3 hours of IFNβ treatment, belong to CXCR2 lig-
and chemokines. Although the analysis in the present
study was a single microarray for each sample design, the
results from two additional subjects, including a 28 year-
old healthy man (the subject #2) and a 27 year-old
woman with RRMS who was a dropout of IFNβ treatment
due to induction of frequent severe relapses (the subject
#4), verified the observations of immediate early induc-
tion of CXCR3 ligand and CCR2 ligand chemokine genes
in PBMC by exposure to IFNβ, supporting the reproduci-
bility of these results (see Additional file 7).
Table 3: Top 20 downregulated genes in PBMC following exposue to IFNβ
No. Cy5/Cy3 ratio Symbol GenBank Gene name
at 3 hours
1 0.29 RGS14 NM_006480 regulator of G-protein signaling 14
2 0.30 FOS NM_005252 cellular oncogene c-fos
3 0.31 SCYB2 NM_002089 chemokine (C-X-C motif) ligand 2 (GRO2, MIP2A)
4 0.41 PPARG2 U63415 peroxisome proliferative activated receptor gamma, isoform 2
5 0.41 TNFSF11 NM_003701 tumor necrosis factor ligand superfamily, member 11 (RANKL), isoform 1
6 0.42 ABCC4 NM_005845 ATP-binding cassette, subfamily C, member 4 (MRP4)
7 0.42 MERTK NM_006343 c-mer proto-oncogene tyrosine kinase
8 0.42 TGFBR3 NM_003243 transforming growth factor beta receptor III (betaglycan)
9 0.44 ATP2B1 J04027 ATPase, Ca++ transporting, plasma membrane 1, isoform 1b
10 0.45 SCYB1 NM_001511 chemokine (C-X-C motif) ligand 1 (GRO1, MGSA)
11 0.45 IL8 NM_000584 interleukin 8 (SCYB8, CXCL8)
12 0.45 TRAF5 NM_004619 TNF receptor-associated factor 5, variant 1
13 0.47 CD3G NM_000073 CD3G antigen, gamma polypeptide
14 0.47 IL1A NM_000575 interleukin 1 alpha
15 0.47 TCFL5 NM_006602 transcription factor-like 5
16 0.48 LAT AF036905 linker for activation of T cells, isoform b
17 0.48 HNMT U08092 histamine N-methyltransferase, isoform 1
18 0.48 SLC3A1 NM_000341 solute carrier family 3, member 1
19 0.49 MGST1 NM_145764 microsomal glutathione S-transferase 1, variant 1d
20 0.49 TNFSF8 NM_001244 tumor necrosis factor ligand superfamily, member 8 (CD30L)
at 24 hours
1 0.18 ABCC3 AF083552 ATP-binding cassette, subfamily C, member 3, isoform MRP3
2 0.20 FOS NM_005252 cellular oncogene c-fos
3 0.30 ALDH2 NM_000690 aldehyde dehydrogenase 2 family
4 0.30 TPST1 NM_003596 tyrosylprotein sulfotransferase 1
5 0.31 CD9 NM_001769 CD9 antigen
6 0.34 NRG1 NM_013962 neuregulin 1, isoform GGF2
7 0.35 TLR5 NM_003268 toll-like receptor 5
8 0.36 PTGS1 NM_000962 prostaglandin-endoperoxide synthase 1 (COX1), isoform 1
9 0.37 MGST2 NM_002413 microsomal glutathione S-transferase 2
10 0.38 ITGAM NM_000632 integrin, alpha M (CD11B, MAC-1, CR3A)
11 0.38 SCYA24 NM_002991 chemokine (C-C motif) ligand 24 (eotaxin 2)
12 0.38 CYP27A1 NM_000784 cytochrome P450, family 27, subfamily A, polypeptide 1 (CTX)
13 0.39 ALDH1A1 NM_000689 aldehyde dehydrogenase 1 family, member A1
14 0.39 MYCL1 NM_005376 v-myc myelocytomatosis viral oncogene homolog 1 (LMYC)
15 0.41 ATP6AP2 NM_005765 ATPase, H+ transporting, lysosomal accessory protein 2 (ATP6M8-9)
16 0.44 PRKCG NM_002739 protein kinase C gamma
17 0.45 ATP2B1 J04027 ATPase, Ca++ transporting, plasma membrane 1, isoform 1b
18 0.46 AP1S2 NM_003916 adaptor-related protein complex 1, sigma 2 subunit
19 0.47 NR6A1 NM_001489 nuclear receptor subfamily 6, group A, member 1 (RTR), isoform 2
20 0.47 GCG NM_173916 glucagon
Top 20 downregulated genes in PBMC of the subject #1 (a 46 year-old healthy man) by exposure to 50 ng/ml recombinant human IFNβ for 3 or 24 
hours are listed with Cy5/Cy3 signal intensity ratio, gene symbol, GenBank accession number, and gene name.BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Real-time RT-PCR analysis validated IFNβ-regulated 
expression of IRGs identified by microarray analysis
Although the microarray we utilized contains total 64
spots of the G3PDH gene (see Additional file 1), G3PDH
was neither identified as a significantly upregulated nor a
downregulated gene in the microarray analysis, suggesting
that G3PDH represents a reliable housekeeping gene in
gene expression analysis of PBMC following treatment
with IFNβ. Therefore, quantitative real-time RT-PCR anal-
ysis was performed by evaluating the levels of expression
of target genes standardized against those of G3PDH
detected in the identical cDNA samples. It verified the key
observations of microarray analysis, such as marked
upregulation of ISG15, the prototype of IRGs (Figure 1a–
c), and great elevation of SCYB10, SCYA8 and SCYA2 (Fig-
ures 2, 3, 4a–c) in PBMC at both 3 and 24 hours of IFNβ
treatment. Furthermore, the quantitative analysis con-
firmed substantial downregulation of FOS at both time
points (Figure 5a–c), and RGS14 and SCYB2 predomi-
nantly at 3 hours (Figures 6, 7a–c). Exposure of PBMC to
IFNγ greatly elevated the expression of SCYB10 and
SCYA2, and to a lessor extent, ISG15 and SCYA8 at both
time points (Figures 1, 2, 3, 4d), suggesting a functional
overlap in induction of CXCR3 ligand and CCR2 ligand
chemokines between type I and type II IFN signaling path-
ways. In contrast, TNFα and IL-1β the prototype of proin-
flammatory cytokines, did not at all elevate the levels of
expression of ISG15, SCYB10 or SCYA8 (Figures 1, 2, 3e,
f), while IL-1β significantly (p = 0.041 at 3 hours and p =
0.004 at 24 hours by two-sided paired t-test) but TNFα
only marginally (p = 0.2102 at 3 hours and p = 0.0825 at
24 hours by two-sided paired t-test) upregulated SCYA2
expression (Figure 4e, f). Treatment with IFNγ, TNFα or
IL-1β reduced the levels of FOS and RGS14 substantially
at 24 hours (Figures 5, 6d–f). IFNγ reduced the expression
of SCYB2, whereas TNFα and IL-1β elevated its levels at
both time points, suggesting differential regulation of
SCYB2 gene expression in PBMC by exposure to distinct
cytokines (Figure 7d–f). The IFNβ-regulated gene expres-
sion pattern was similar among PBMC derived from three
distinct healthy subjects #1, #2 and #3, supporting the
reproducibility of these observations (Figures 1, 2, 3, 4, 5,
6, 7a–c).
Table 4: Functional classification of IFNβ-upregulated genes in PBMC
Categories Number 
of genes
Gene symbols (alternative symbols or names)
1 Conventional IFN-response markers 12 IFIT1 (IFI56), ISG15 (G1P2), IFIT4 (IFI60), MX1 (MXA), MX2 (MXB), 
IFI27, G1P3 (IFI6-16), ISG20, IFI16, IFITM1 (IFI17), IFITM3 (1-8U), 
ABCB2 (TAP1)
2 Components of IFN-signaling pathways 12 STAT1, IRF7, STAT2, JAK2, IRF2, ISGF3G (IRF9), MYD88, IRF8, 
STAT3, JAK3, IRF1, TLR3
3 Chemokines and receptors 11 SCYB11 (CXCL11, I-TAC), SCYB10 (CXCL10, IP-10), SCYA8 (CCL8, 
MCP2), SCYB9 (CXCL9, MIG), SCYA2 (CCL2, MCP1), CCR5, SCYA4 
(CCL4, MIP1B), IL8RB (CXCR2), SCYA3 (CCL3, MIP1A), SCYA19 
(CCL19, MIP3B), SCYA13 (CCL13, MCP4)
4 Cytokines, growth factors, and receptors 17 IL6, ILRN (IL-1 receptor antagonist), IL1R2, IL15RA, IL15, SPP1 
(osteopontin), CSF1, IL12RB2, TNF (TNFA), IL2RB, IFNG, NTRK1 
(TRKA), PDGFRL, TNFAIP6, KITLG (SCF), IL10, IL3RA
5 Apotosis, DNA damage, and cell cycle regulators 29 TNFSF10 (TRAIL), CASP10, BAG1, TNFRSF6 (FAS), CASP4, TRADD, 
GZMA, CASP7, RIPK2, MAD, RIPK1, CFLAR (FLIP), RELA, STK3, 
CASP1, TNFSF6 (FASL), PARP4, TANK (I-TRAF), POLE2, LMNB1, 
E2F2, CCNA1 (cyclin A1), CDKN1A (p21), PPP1R15A (GADD34), 
CASP3, CDKN1C (p57), CDK5R2 (p39), TERF1, NBS1 (nibrin)
6 Heat shock proteins 9 HSPA6 (HSP70B'), HSJ2 (HSPF4), HSPA1A (HSP70-1), HSPA1B 
(HSP70-2), HSPCA (HSP90A), HSPA5 (GRP78), HSPA1L (HSP70-
HOM), HSPA8 (HSC70), HSPB1 (HSP27)
7 Costimulatory and adhesion molecules 7 CD80 (B7-1), SELL (selectin L), TNFRSF5 (CD40), CD163, CD86 (B7-
2), HLA-DRA, FCER1G
The upregulated IRGs in PBMC listed in Additional files 3 and 5 were classified into seven functional categories.BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Real-time RT-PCR analysis of ISG15 expression in PBMC Figure 1
Real-time RT-PCR analysis of ISG15 expression in PBMC. PBMC derived from three distinct healthy subjects numbered #1 (a 46 
year-old man), #2 (a 28 year-old man), and #3 (a 42 year-old woman) were incubated for 3 hours or 24 hours in the culture 
medium with (+) or without (-) inclusion of recombinant human IFNβ, IFNγ, TNFα or IL-1β at a concentration of 50 ng/ml 
each. cDNA was processed for real-time PCR analysis using specific primers listed in Table 1. The levels of expression of ISG15 
are standardized against those of the glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene detected in identical cDNA 
samples. The assays were performed in triplicate measurements of the same sample, and the results were expressed as the 
average with standard error. The panels represent the expression of ISG15 in (a) #1, IFNβ; (b) #2, IFNβ; (c) #3, IFNβ; (d) #1, 
IFNγ; (e) #1, TNFα; and (f) #1, IL-1β.
(a) (b) (c)
(d) (e) (f)BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Real-time RT-PCR analysis of SCYB10 expression in PBMC Figure 2
Real-time RT-PCR analysis of SCYB10 expression in PBMC. See the footnote of Figure 1. The panels represent the expression of 
SCYB10 in (a) #1, IFNβ; (b) #2, IFNβ; (c) #3, IFNβ; (d) #1, IFNγ; (e) #1, TNFα; and (f) #1, IL-1β.
(a) (b) (c)
(d) (e) (f)BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Real-time RT-PCR analysis of SCYA8 expression in PBMC Figure 3
Real-time RT-PCR analysis of SCYA8 expression in PBMC. See the footnote of Figure 1. The panels represent the expression of 
SCYA8 in (a) #1, IFNβ; (b) #2, IFNβ; (c) #3, IFNβ; (d) #1, IFNγ; (e) #1, TNFα; and (f) #1, IL-1β.
(a) (b) (c)
(d) (e) (f)BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Real-time RT-PCR analysis of SCYA2 expression in PBMC Figure 4
Real-time RT-PCR analysis of SCYA2 expression in PBMC. See the footnote of Figure 1. The panels represent the expression of 
SCYA2 in (a) #1, IFNβ; (b) #2, IFNβ; (c) #3, IFNβ; (d) #1, IFNγ; (e) #1, TNFα; and (f) #1, IL-1β.
(a) (b) (c)
(d) (e) (f)BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Real-time RT-PCR analysis of FOS expression in PBMC Figure 5
Real-time RT-PCR analysis of FOS expression in PBMC. See the footnote of Figure 1. The panels represent the expression of FOS in 
(a) #1, IFNβ; (b) #2, IFNβ; (c) #3, IFNβ; (d) #1, IFNγ; (e) #1, TNFα; and (f) #1, IL-1β.
(a) (b) (c)
(d) (e) (f)BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Real-time RT-PCR analysis of RGS14 expression in PBMC Figure 6
Real-time RT-PCR analysis of RGS14 expression in PBMC. See the footnote of Figure 1. The panels represent the expression of 
RGS14 in (a) #1, IFNβ; (b) #2, IFNβ; (c) #3, IFNβ; (d) #1, IFNγ; (e) #1, TNFα; and (f) #1, IL-1β.
(a) (b) (c)
(d) (e) (f)BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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Discussion
IFNs are a family of cytokines that mediates antiviral, anti-
proliferative and immunoregulatory activities. Type I
IFNs, IFNα and β, are produced principally by virus-
infected host cells, whereas type II IFN, IFNγ, is produced
by activated T cells and natural killer (NK) cells. Type I
IFNs activate JAK protein tyrosine kinases associated with
the cell surface receptors for IFNs, leading to formation of
the complex of signal transducer and activator of tran-
scription (STAT) molecules with the IFN regulatory factor
(IRF) family of transcription factors. The STAT/IRF com-
plex translocates into the nucleus, and binds to the DNA
sequences termed the IFN-stimulated response element
(ISRE) or the IRF-recognition element (IRE). This binding
subsequently activates transcription of a wide variety of
IFN-responsive genes (IRGs) as well as the genes of type I
and type II IFNs, leading to the biological responses trig-
gered by the IFNs [24]. Both type I and type II IFNs
enhance the expression of class I and class II MHC mole-
cules [25]. Among nine distinct IRFs, IRF7 and IRF3 play
a central role in induction of type I IFN genes via the virus-
activated MYD88-independent pathway or Toll-like recep-
tor (TLR)7, 8 or 9-activated MYD88-dependent pathway
[26], while IRF1 plays more active roles in induction of
IFNγ-target genes essential for Th1-type immune response
[25].
The present study by analyzing DNA microarray character-
ized a comprehensive list of immediate early IRGs in
PBMC in vitro. Following a 3 to 24 hour-exposure to IFNβ,
upregulated genes greatly outnumbered downregulated
genes. All top 20 upregulated genes represent known IRGs
previously identified in various cell types. The upregu-
lated IRGs of PBMC were classified into several functional
categories. The list included not only conventional IFN-
response markers and components of IFN-signaling path-
ways, but also contained many proinflammatory chemok-
ines and cytokines. This is surprising because IFNβ acts
principally as an anti-Th1, anti-inflammatory cytokine
[6,7]. By analyzing global gene expression profile, the
present study for the first time showed that IFNβ induced
a burst of gene expression of CXCR3 ligand chemokines
Real-time RT-PCR analysis of SCYB2 expression in PBMC Figure 7
Real-time RT-PCR analysis of SCYB2 expression in PBMC. See the footnote of Figure 1. The panels represent the expression of 
SCYB2 in (a) #1, IFNβ; (b) #2, IFNβ; (c) #3, IFNβ; (d) #1, IFNγ; (e) #1, TNFα; and (f) #1, IL-1β.
(a) (b) (c)
(d) (e) (f)BMC Neurology 2006, 6:18 http://www.biomedcentral.com/1471-2377/6/18
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(SCYB11, SCYB10 and SCYB9) and CCR2 ligand chemok-
ines (SCYA8 and SCYA2), which was verified by quantita-
tive real-time RT-PCR analysis. The chemokine genes
actually have ISRE or IRE in the promoter regions, indicat-
ing direct targets of IFNβ[27,28].
CXCR3 is expressed predominantly on activated Th1 T
cells, while CCR2 is expressed chiefly on monocytes [29].
The number of CXCR3+ T cells is increased in the blood of
RRMS, and they accumulate in perivascular infiltrates in
active MS lesions [30,31], while SCYB10 (IP-10) and
SCYB9 (MIG) are detected in the cerebrospinal fluid
(CSF) of RRMS at acute relapse and expressed in reactive
astrocytes in active MS lesions [31,32]. SCYA2 (MCP1)
and SCYA8 (MCP2) immunoreactivities are also identi-
fied in reactive astrocytes in active demyelinating lesions
of MS [33,34]. These observations suggest that CXCR3,
CCR2, and their ligand chemokines positively regulate
active inflammation in MS. Although the precise cell types
expressing CXCR3 ligand and CCR2 ligand chemokines in
PBMC in response to IFNβ remain to be characterized, the
chemokine burst plays a central role in rapid activation
and systemic recruitment of Th1 T cells and monocytes
immediately after initiation of IFNβ treatment. A recent
study showed that IFNβ promotes trafficking of mouse
leukocytes by regulating a specific set of chemokines [35].
However, concurrent upregulation of a set of CXCR3 and
CCR2 ligand chemokines has not previously been
reported in MS patients on a long-term IFNβ treatment
[16,17,20-22], suggesting that this phenomenon is an
immediate early but transient event in vivo. IFNβ immedi-
ately reduced the expression of RGS14 (the most signifi-
cantly downregulated gene at 3 hours; see Table 3), a
member of the regulator of G protein signaling (RGS)
gene family that acts as a negative regulator of G protein-
coupled receptor (GPCR) signaling. Since all chemokine
receptors are GPCR, IFNβ-induced downregulation of
RGS14 might facilitate chemokine responsiveness in the
cells expressing RGS14 [36,37]. Much less is known about
the mechanism for regulation of IFNβ-repressed genes
[38]. We identified IL-8 as one of IFNβ-repressed genes in
PBMC (Table 3). IFNβ inhibits the transcription of IL-8
gene, possibly by binding of NF-κB repressing factor
(NRF) to a negative regulatory element of the IL-8 pro-
moter [39]. Serum IL-8 levels and IL-8 secretion from
PBMC are elevated in untreated MS, and then reduced fol-
lowing IFNβ therapy [40]. Downregulation of IL-8 expres-
sion in PBMC during IFNβ treatment provides a predictive
indicator for the responders in RRMS [20].
IFNβ also promptly upregulated a variety of proinflam-
matory cytokines, such as IL-6, IL-15, osteopontin, TNFα,
and IFNγ in PBMC (Table 4). IFNβ promotes production
of TNFα and IFNγ in unstimulated PBMC but decreases
their levels in preactivated PBMC [41-43]. IFNβ increases
the number of IFNγ-secreting cells in vivo at the early
period of the treatment [44]. Most importantly, proin-
flammatory cytokines and chemokines induced by IFNβ
have relevance to treatment-related early adverse effects.
There exists a close relationship between flu-like symp-
toms and increased levels of IL-6 [45]. A single injection
of IFNβ induces a transient burst of SCYB10 (IP-10) in the
plasma of RRMS patients, which correlates with an inci-
dence of flu-like symptoms [46]. IFNβ enhances the
expression of CD80, SCYB10 (IP-10) and SCYA2 (MCP1)
in situ at sites of injection, leading to chemotaxis of lym-
phocytes and monocytes in the lesions of skin reaction
[47-49]. We found that IFNβ aberrantly regulated the lev-
els of expression of several cytochrome P450 (CYP)
enzymes (see Additional files 3,4,5,6). Type I IFN reduces
the activity of CYP enzymes that metabolize various
endogenous and exogenous substrates, probably leading
to an increase in the potential for IFN-related hepatotox-
icity [50].
Finally, the list of IRGs included various apoptosis regula-
tors and HSP family members. ISRE-like sequences are
identified in the regulatory element of CASP1, CASP4,
CASP8, TNFRSF6 (FAS), TNFSF6 (FASL) and TNFSF10
(TRAIL), suggesting that IFNβ acts as a proapototic
cytokine [51,52]. A recent study showed that early and
sustained induction of TRAIL provides a marker for IFNβ
treatment response in MS [53]. Furthermore, IFNβ-induc-
ible apoptosis regulators play an immunoregulatory role.
TNFR1-associated via death domain (TRADD) inhibits
IFNγ-induced STAT1α activation [54]. Receptor-interact-
ing serine-theronine kinase 1 (RIPK1) regulates TLR3-
independent viral double-stranded RNA-induced type I
IFN production [55]. Because HSPs in general act as an
anti-apoptotic defender, the induction of HSP gene
expression might occur as a counterbalance against upreg-
ulation of proapoptotic regulators. Alternatively, IRGs
could directly enhance HSP expression. IFNβ-induced
STAT1, by interacting with heat shock factor-1 (HSF1),
activates the HSP70 and HSP90β gene promoters [56].
Conclusion
Microarray analysis showed that IFNβ immediately
induces a burst of gene expression of proinflammatory
chemokines and cytokines in vitro that have potential rel-
evance to IFNβ-related early adverse effects in MS patients
in vivo.
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